20/10/2024
Scientists Have Created a Drug That Could Reverse Heart Attack Damage:
A molecule found in spider venom may be able to reverse tissue damage after a heart attack, and it's going to clinical trials.
So far, the only other cardioprotective drug to make it to a Phase III clinical trial was not approved because it led to strokes.
The experimental molecule, called Hi1a, is designed to block a specific cellular pathway that triggers heart cell death during an attack. Initial trials will assess its safety, with hopes that it could become the first treatment directly targeting tissue injury from heart attacks, potentially available not just in hospitals but also through first responders in the future.
Hi1a works by targeting the acid-sensing ion channel 1a (ASIC1a), a passageway that becomes overactive during heart attacks due to oxygen deprivation. Typically, these channels allow acidic molecules to flood heart cells, leading to tissue death. Hi1a blocks this process, preventing damage. Preclinical tests in mice and human heart cells showed that the drug effectively reduced tissue injury caused by restricted blood flow. If successful in early human trials, Hi1a could also be used to protect donor hearts during transplantation, increasing the availability of viable organs.
Despite promising results, previous cardioprotective drugs have faced significant challenges, with many failing to advance beyond animal trials. Dr. Heerajnarain Bulluck, a cardiologist at the University of Leeds, cautioned that the only cardioprotective drug to reach a Phase III trial was ultimately rejected due to stroke risks. Researchers are optimistic, but the full development process will take years, with larger Phase II and Phase III trials needed to confirm safety and efficacy across a wider population.
